@BrightStars @Flyhai Mark Strome is a director and loaded up on shares. He also is a major holder in $ZIVO and that has also been a terrible performing stock. I believe he bought shares at a high of $16 and it now barely trades at $4. He used to be a great investor but has a terrible record now.
$ZIVO Strome is a big holder in $BEAT.X and this stock appears on its way to zero. If he was to liquidate his position in Zivo to cover any losses in $BEAT , it’s going to get ugly.
$ZIVO Looks like the presentation is on You Tube now
https://www.youtube.com/channel/UCg4aDJl8JSdTrly_xTHGJhA
Apparently multiple irons in the fire to expand the algae business either via standalone or ingredient verticals. POCing gummies as a delivery format. Multiple NDAs here. Lotta compare to spirulina. ZIVO algae better on all the key measures. Potential for replacement of spirulina in formulations.
University of Georgia didn't get alot of play and no specifics but testing the algae as a component of their gov't grant award for avian flu is in the testing protocols phase apparently.
Partner for coccidiosis doing dosing study after which there's a 90 day window to exclusively formalize license (assuming all goes well).
Cyanotech came up a couple times. Yaldoo didn't specifically know the grow cycle but I'm 99% sure it's basically 2 weeks under normal conditions. A little more to start from scratch. Made in the USA, cheap shipping, plenty of expansion capacity, no tariffs.
I thought Q&A part was better
$ZIVO disappointed Zivo has not signed a revenue generating deal with a food processor. They are leaving a tremendous amount of money on the table and continue to fail to execute. Bewildering why Yaldoo, Strome, and Maggiore do not push harder for this company to execute.
$ZIVO 2 shares on big news....
warrants are WORTHLESS....Nov/Dec heavy tax losses.....No one will pay $$$ for this...18 years of failures.....
Epic Failure
$ZIVO @trprofit I see you beat me to posting this update over here. Good news in that many thought coccidiosis was dead. Obviously not with a major animal pharma further agreeing to take on a commercial scale test. Fits within the compliance guidelines as we all know these tests have to get to commercial size. I figure results are early August timeframe on this. I'm still of the opinion a pharma deal for coccidiosis makes this a $50 stock. Validation and doors open to more verticals.
No real market reaction cause 99.9% of the public and of ZIVO investors haven't seen this update. Of course I anticipate this update will be met with a "yawn" .... i.e. another test. Dunno if this is a new pharma or prior pharma taking the next step .... but commercial scale test .... with intent to find minimum dosage ... determines the economics of commercial viability.
Of course we all know this stuff works. Just a matter of money at this point.
$ZIVO I reviewed the Q1 filing. Expenses significantly cut. Once revenue is generated it will flow right to net profit. Remeber, Zivo has a massive carryover loss to apply against future profits. This is going to pop once a deal is signed. Leadership of this company finally understands Zivo is not a never ending science experiment and needs to be run like a business.
